Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/Compare

TSLA vs LCID

TSLA and LCID side by side — valuation & fundamentals (public data).

Key statistics

TSLA vs LCID key statistics
MetricTSLATesla, Inc.LCIDLucid Group, Inc.
Market cap$1.44T$1.59B
P/E (TTM)336.6—
P/B16.53—
P/S15.1x1.2x
Revenue$103.62B(TTM)—
Revenue growth (YoY)-2.9%67.6%
Net income$3.80B(TTM)—
Earnings growth (YoY)-46.5%0.6%
EPS, diluted$1.08(TTM)—
EBIT margin4.6%-258.7%
ROE4.4%—
ROIC4.3%-327.5%
Piotroski F5/92/9
1y total return-13.8%-79.1%

Figures from SEC filings · for reference only · not investment advice

Growth of $10,000: TSLA vs LCID

$10.0K$24.7K$4082020-09-182026-09-16
MetricTSLALCID
End value$24.7K$408
Total return+146.8%-95.9%
CAGR+16.3%-41.4%
Volatility59.1%88.2%
Sharpe0.48-0.23
Sortino0.71-0.35
Max drawdown-73.6%-99.3%

Based on 1505 common trading days, 2020-09-18 → 2026-09-16 · risk-free 4.11% (current short-Treasury, held constant)

A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.

Related comparisons

TSLA vs NVDARIVN vs LCIDRIVN vs TSLALCID vs TSLAF vs TSLAGM vs TSLA

Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)